| Literature DB >> 36015950 |
Agnieszka Krakos Podwin1, Joanna Jarosz2, Patrycja Śniadek1, Mateusz Psurski2, Adrianna Graja1,3, Marcin Białas1, Ewa Oliszewska2, Joanna Wietrzyk2, Rafał Walczak1, Jan Dziuban1.
Abstract
In the paper, the lab-on-chip platform applicable for the long-term cultivation of human cancer cells, as a solution meeting the demands of the CubeSat biological missions, is presented. For the first time, the selected cancer cell lines-UM-UC-3 and RT 112 were cultured on-chip for up to 50 days. The investigation was carried out in stationary conditions (without medium microflow) in ambient temperature and utilizing the microflow perfusion system in the incubation chamber assuring typical cultivation atmosphere (37 °C). All the experiments were performed to imitate the conditions that are provided before the biological mission starts (waiting for the rocket launch) and when the actual experiment is initialized on a CubeSat board in space microgravity. The results of the tests showed appropriate performance of the lab-on-chip platform, especially in the context of material and technological biocompatibility. Cultured cells were characterized by adequate morphology-high attachment rate and visible signs of proliferation in each of the experimental stage. These results are a good basis for further tests of the lab-on-chip platform in both terrestrial and space conditions. At the end of the manuscript, the authors provide some considerations regarding a potential 3-Unit CubeSat biological mission launched with Virgin Orbit company. The lab-on-chip platform was modelled to fit a 2-Unit autonomous laboratory payload.Entities:
Keywords: cancer cell cultivation; glass micromachining; lab-on-chip; microfluidic payload; space biology mission
Mesh:
Year: 2022 PMID: 36015950 PMCID: PMC9414851 DOI: 10.3390/s22166183
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.847
CubeSat type biological missions—overview.
| GeneSat-1 | PharmaSat | O/OREOS | SporeSat | EcAMSat | Biosentinel | ||
|---|---|---|---|---|---|---|---|
| Nanosatellite configuration | 2 U payload, 1 U bus | 2 U payload, 1 U bus | 2 × 1 U payloads, | 2 U payload, 1 U bus | 3 U payload, 3 U bus | 4 U payload, 2 U bus | |
| Experiment type | Gene | Drug | Viability of | Chemical degradation (PAH, amino acid, | Gravity sensing of plant spores | Drug | DNA damage of |
| Detection methods | GFP fluorescence | Optical absorbance | Colorimetry (dye indicator) | UV–VIS spectroscopy | Conductivity of spores | Colorimetry (dye indicator) | Colorimetry (dye indicator) |
| Launch date | 2006 | 2009 | 2010 | 2014 | 2017 | 2022 | |
Figure 1Overall schematic view of the payload for CubeSat type nanosatellite implementing biomedical experimentation.
Figure 2LOC platform: (a) detailed scheme, (b) platform under operation.
Figure 3The concept of the LOC for culturing of human cancer cells: top view (on the left), cross-section (on the right). Dimensions are given in millimeters.
Figure 4Fabrication of the LOCs for culturing of cancer cells—technology flow.
Figure 5All-glass LOCs at a glance.
Cell lines and culture media used in the present study.
| No | Cel Line | Type of Cancer | Purchased from | Medium * |
|---|---|---|---|---|
| 1 | A549 | lung carcinoma | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | RPMI 1640 + OptiMEM medium (1:1) (HIIET, PAS, Wroclaw, Poland) with 5% ( |
| 2 | A498 | kidney carcinoma | American Type Culture Collection (ATCC, Manassas, VA, USA) | Opti-Mem + GlutaMax (Invitrogen, Waltham, MA, USA) and RPMI1640 + GlutaMAX (Life Technologies, Renfrew, UK) (1:1) medium with 5% ( |
| 3 | 5637 | urinary bladder TCC | Riken BRC Cell Bank | RPMI1640 + GlutaMAX with 10% ( |
| 4 | RT-112 | urinary bladder TCC | RCCL (Resistant Cancer Cell Line Collection) | Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, Renfrew, UK) with 10% ( |
| 5 | TCC-SUP | urinary bladder TCC | German Collection of | DMEM with 10% ( |
| 6 | UM-UC-3 | urinary bladder TCC | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | DMEM with 10% ( |
| 7 | UM-UC-3/CDDP | urinary bladder TCC, resistant to cisplatin | ECACC, established at Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences (HIIET, PAS, Wroclaw, Poland | DMEM with 10% ( |
| 8 | UM-UC-3/GEM | urinary bladder TCC, | ECACC, established at Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences (HIIET, PAS, Wroclaw, Poland | DMEM with 10% ( |
| 9 | UM-UC-3/VBL | urinary bladder TCC, resistant to vinblastine | ECACC, established at Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences (HIIET, PAS, Wroclaw, Poland | DMEM, supplemented with 10% ( |
| 10 | HCT116 | colon carcinoma | American Type Culture Collection (ATCC, Manassas, VA, USA) | McCoy’s 5 A medium (Life Technologies, Renfrew, UK) supplemented with 10% ( |
| 11 | HT29 | colon adenocarcinoma | American Type Culture Collection (ATCC, Manassas, VA, USA) | RPMI 1640 + OptiMEM medium (1:1) supplemented with 5% ( |
| 12 | LoVo | colon adenocarcinoma | American Type Culture Collection (ATCC, Manassas, VA, USA), | F-12K Nutrient Mixture (F-12K; Corning, Corning, USA), supplemented with 10% ( |
| 13 | LoVo/DX | colon adenocarcinoma, resistant to doxorubicin | American Type Culture Collection (ATCC, Manassas, VA, USA) | F-12K Nutrient Mixture, supplemented with 10% ( |
| 14 | A2780 | ovary carcinoma, epithelial | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | RPMI1640 + GlutaMAX containing 10% ( |
| 15 | A2780/CDDP | ovary carcinoma, epithelial, resistant to cisplatin | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | RPMI1640 + GlutaMAXcontaining 10% ( |
| 16 | SKOV-3 | ovary adenocarcinoma | American Type Culture Collection (Rockville, MD, USA) | McCoy’s 5A medium, supplemented with 10% ( |
| 17 | MCF-7 | mammary gland adenocarcinoma | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | Eagle’s medium (HIIET, PAS, Wroclaw, Poland), supplemented with 10% ( |
| 18 | MDA-MB-231 | mammary gland adenocarcinoma | American Type Culture Collection (ATCC, Manassas, VA, USA) | RPMI 1640 (HIIET, PAS, Wroclaw, Poland), supplemented with 10% ( |
| 19 | PC-3 | prostate adenocarcinoma | European Collection of Authenticated Cell Cultures (ECACC, Porton Down, UK) | RPMI 1640, supplemented with 10% ( |
* All culture media were supplemented with antibiotics—100 µg/mL streptomycin (Polfa-Tarchomin, Warsaw, Poland) and 100 U/mL penicillin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany).
Set of compounds and their concentration ranges utilized for antiproliferative assay.
| Compound | Concentration Ranges [µM] | Manufacturer |
|---|---|---|
| Paclitaxel | 0.1–0.0001 | Fresenius Kabi |
| Cisplatin | 100–0.1 | Accord |
| 5-Fluorouracil | 100–0.1 | Accord |
| Etoposide | 100–0.1 | Sigma-Aldrich |
| Gemcitabine | 0.1–0.001 | Sigma-Aldrich |
| Doxorubicin | 1–0.001 | Sigma-Aldrich |
Characteristics of cancer cell growth (proliferation) on the LOC platform using a standard (cell line-optimized) culture medium.
| Cell Line | Cell Line Type | Growth Rating After * | ||
|---|---|---|---|---|
| 24 h | 72 h | 120 h | ||
| A549 | lung carcinoma | ++/++ | ++/++ | −/++ |
| A498 | kidney carcinoma | ++/++ | ++/+ | +/++ |
| 5637 | urinary bladder TCC | +/− | +/− | −/− |
| RT-112 | urinary bladder TCC | ++/++ | +++/+++ | +/+++ |
| TCC-SUP | urinary bladder TCC | ++/+ | +++/++ | +++/+++ |
| UM-UC-3 | urinary bladder TCC | ++/+ | ++/++ | +/+++ |
| UM-UC-3/CDDP | urinary bladder TCC, resistant to cisplatin | ++/− | +/− | −/− |
| UM-UC-3/GEM | urinary bladder TCC, | −/− | −/− | −/− |
| UM-UC-3/VBL | urinary bladder TCC, resistant to vinblastine | ++/− | −/− | −/− |
| HCT116 | colon carcinoma | ++/+ | ++/++ | +/+++ |
| HT29 | colon adenocarcinoma | ++/++ | +++/++ | +/++ |
| LoVo | colon adenocarcinoma | ++/++ | +/+++ | +/+++ |
| LoVo/DX | colon adenocarcinoma, resistant to doxorubicin | +/+ | +/− | +/− |
| A2780 | ovary carcinoma, epithelial | +/+ | +/− | +/− |
| A2780/CDDP | ovary carcinoma, epithelial, resistant to cisplatin | −/+ | −/− | −/− |
| SKOV-3 | ovary adenocarcinoma | +++/+++ | +++/+++ | −/++ |
| MCF-7 | mammary gland adenocarcinoma | +/+ | ++/+ | ++/+++ |
| MDA-MB-231 | mammary gland adenocarcinoma | +/− | +/+ | ++/++ |
| PC-3 | prostate adenocarcinoma | +/+ | ++/+ | ++/++ |
x/y—cells seeded high/low density (5 × 104 and 104, respectively); * +++—high attachment rate, visible signs of proliferation and colonies formation; ++—low attachment rate, no signs of proliferation nor colonies formation; +—no attachment, but no signs of cell death; −—significant signs of cell death. Tests were performed in reference to control cultures representing +++/+++.
Figure 6Representative images showing distinct cells attachment efficacy on LOC (mainly analyzed after 24 h), proliferation efficiency, colonies formation, cells morphology, and signs of cell death, such as cells rounding and detachment (analyzed after 72–120 h).
Characteristics of cancer cell growth (proliferation) on the LOC platform utilizing CO2-independent medium.
| Cell Line | Cell Line Type | Growth Rating After * | ||
|---|---|---|---|---|
| 24 h | 72 h | 120 h | ||
| A549 | lung carcinoma | ++/++ | ++/++ | −/++ |
| A498 | kidney carcinoma | +/+ | ++/+ | +/++ |
| RT-112 | urinary bladder TCC | ++/++ | +++/+++ | +/+++ |
| TCC-SUP | urinary bladder TCC | +/+ | +++/++ | +++/+++ |
| UM-UC-3 | urinary bladder TCC | ++/++ | ++/++ | +/+++ |
| HT29 | colon adenocarcinoma | +/+ | +++/++ | +/++ |
| LoVo | colon adenocarcinoma | −/+ | −/++ | −/++ |
| SKOV-3 | ovary adenocarcinoma | ++/++ | ++/++ | +/++ |
| MCF-7 | mammary gland adenocarcinoma | +/+ | ++/+ | ++/+++ |
| MDA-MB-231 | mammary gland adenocarcinoma | +/− | +/+ | +/++ |
x/y—cells seeded high/low density (5 × 104 and 104, respectively); * +++—high attachment rate, visible signs of proliferation and colonies formation; ++—low attachment rate, no signs of proliferation nor colonies formation; +—no attachment, but no signs of cell death; −—significant signs of cell death. Tests were performed in reference to control cultures representing +++/+++.
Figure 7Representative images showing UM-UC-3 cells morphology at given conditions after indicated days of incubation. Incubator 37 °C, 5% CO2 (standard growth conditions); heater 37 °C.
Figure 8Representative images showing RT-112 cells morphology at given conditions after indicated days of incubation. Incubator 37 °C, 5% CO2 (standard growth conditions); heater 37 °C.
Figure 9Representative images showing RT-112 cells morphology seeded on LOC platform at given conditions after indicated days of incubation. Incubator 37 °C, 5% CO2 (standard growth conditions); heater 37 °C.
Figure 10Representative images showing UM-UC-3 cells morphology seeded on LOC platform and cultured in the incubator 37 °C, 5% CO2 (standard growth conditions).
Figure 11Representative images showing UM-UC-3 cells morphology seeded on LOC platform and cultured in the heater 37 °C w/o CO2.
Figure 12Representative images showing UM-UC-3 cells morphology cultured at room temperature for 14 days (upper panel) and after transfer to the incubator (lower panel).
Figure 13Dose–response curves obtained for UM-UC-3 cells cultured in standard or experimental conditions for 72 h with selected drugs. Curve fitting was carried out using [Inhibitor] vs. response-Variable slope (four parameters) nonlinear model in GraphPad Prism 7.0 software.
Figure 14Cell cycle profile observed for UM-UC-3 cells cultured in standard or experimental conditions. Data presented as a percentage of the cells in each phase of the cell cycle. G1 stands for the cell growth stage, S for the DNA synthesis stage, and G2 for pre-mitosis stage.
Figure 15Representative images (Day 5) showing UM-UC-3 cells morphology cultured on LOC platform using peristaltic pump-driven medium exchange.
Figure 16Microfluidic 2U payload for the biological nanosatellite cancer cells mission—concept.
Potentially prevailing environmental conditions during the selected steps of the biological nanosatellite mission with a view to our experimentation.
| Step | Phase | Environmental Conditions | Time |
|---|---|---|---|
| 0 | Payload processing facility | 17–25 °C, | ~2–3 weeks |
| 1 | Launchpad activities | 4–27 °C, | ~1–2 days |
| 2 | Flight | Payload will be exposed to an equivalent radiative heat flux emanating from about 93 °C surface with an emissivity of 0.9 | ~1 h |
| 3 | Free-orbiting satellite (space experimentation) | −120 ÷ +120 °C (outer space) [ | ~5 days |
| Overall mission time | ~20–28 days | ||